Generation of in Vitro Autologous Human Cytotoxic T-Cell Response to E7 and HER-2/Neu Oncogene Products Using Ex-Vivo Peptide Loaded Dendritic Cells

  • H. Navabi
  • B. Jasani
  • M. Adams
  • A. S. Evans
  • M. Mason
  • T. Crosby
  • L. Borysiewicz
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 417)

Abstract

Cytotoxic T-cells (CTL) have been shown to be capable of causing tumour-specific cell lysis when primed with tumour-specific antigenic peptides presented in conjunction with haplotype matched cell surface MHC class I molecules. For this approach to be successful for immunotherapy of tumours in vivo, it is essential that it is shown to be capable of generating adequate numbers of tumour-specific CTL either in vivo for active immunisation, or ex vivo for adoptive transfer therapy. A powerful means for ex vivo expansion of CTL has been recently shown to be antigen loaded autologous dendritic cells (DC)1. It has also become possible to generate large numbers of these cells from bone marrow or blood derived precursor cells cultured in the presence of GM-CSF and 1L42. Furthermore, murine studies have confirmed the efficacy of these cells to evoke significant ex vivo and in vivo responses against tumour specific antigenic peptides, in particular, HPV 16 E7 and HER-2/neu oncogene products3, thereby creating the possibility of using these antigenic targets4 for effective immunotherapy of gynaecological cancers such as cervical and ovarian carcinomas in which these tumour associated antigens are expressed with 93%5 and 30%6 frequency, respectively.

Keywords

Cervical Cancer Recombinant Vaccinia Virus Tumour Antigen Peptide Loaded Dendritic Cell Peptide Loaded Dendritic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Saullusto F, Lanzavecchia A, (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin-4 and down regulated by tumour necrosis factor alpha. J Exp Med 179: 1109–1118.CrossRefGoogle Scholar
  2. 2.
    Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacker B, Konwalinka G, Fritsch PO, Steinman and Schuler G, (1994). Proliferating dendritic cell progenitors in human blood. J Exp Med 180, 83–93PubMedCrossRefGoogle Scholar
  3. 3.
    Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, (1995). Bone marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. Nature Medicine 1 (12): 1297–1302PubMedCrossRefGoogle Scholar
  4. 4.
    Dsis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Lydon N, McGlynn E, Moe R, Cheever MA, (1994). Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16–22Google Scholar
  5. 5.
    Bosch FX, Mano MM, Munoz N, Sherman M, (1995). Prevalence of human papilloma virus in cervical cancer: a worldwide perspective. Journal of the National Cancer Institute 87: 796–802PubMedCrossRefGoogle Scholar
  6. 6.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, (1989). Studies of the 14ER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–12PubMedCrossRefGoogle Scholar
  7. 7.
    Borysiewicz LK,Fiander A,Nimako, Man S,Wilkinson GWG, Westmoreland D, Evans AS, Adams M,Stacey SN, Boursnell MEG, Rutherford E, Hickling JK, Inglis SC. (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18,E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347: 1523–27.CrossRefGoogle Scholar
  8. 8.
    Grabbe S,Beissert,Schwartz and Granstein RD (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunology Today 16(3)117–121.Google Scholar
  9. 9.
    Gabrilovich DI Nadaf S,Corak J,Berzofsky JA and Carbonne DP (1996). Dendritic cells in anti-tumour immune responses 11 Dendritic cells grown from bone marrow precursors but not mature DC from tumour bearing mice are effective antigen carriers in the therapy of established tumours. Cellular Immunology 170. 111–119.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • H. Navabi
    • 1
  • B. Jasani
    • 2
  • M. Adams
    • 1
  • A. S. Evans
    • 4
  • M. Mason
    • 1
  • T. Crosby
    • 1
  • L. Borysiewicz
    • 3
  1. 1.Department of Clinical OncologyVelindre NHS Trust WhitchurchCardiffUK
  2. 2.Department of PathologyUHW Healthcare NHS TrustCardiffUK
  3. 3.Department of MedicineUHW Healthcare NHS TrustCardiffUK
  4. 4.Department of GynaecologyUHW Healthcare NHS TrustCardiffUK

Personalised recommendations